- Outlook Therapeutics ( NASDAQ: OTLK ) announced the full cash pre-payment of its unsecured convertible promissory note (as amended on Nov.16, 2021).
- The company requires a good financial position to support the potential FDA approval and subsequent launch of ONS-5010/ LYTENAVA.
- "We are pleased to be in a position to fully repay this unsecured convertible promissory note to prevent the dilution associated with redemption of the Note for common stock at a 25% discount to market price that could have begun on July 1, 2022," CFO Lawrence A. Kenyon commented.
For further details see:
Outlook Therapeutics announces full cash pre-payment of convertible promissory note